We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassays Correlated With Systemic Lupus Erythematosus Activity

By LabMedica International staff writers
Posted on 15 Sep 2011
Print article
Three immunoassays have been compared for their ability to monitor the progression of the disease systemic lupus erythematosus (SLE).

Quantitative measurement of anti-double stranded DNA (dsDNA) antibodies plays a central role in monitoring the autoimmune connective tissue disease SLE, and results are incorporated into the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K).

Scientists at the University Health Network (Toronto, ON, Canada) analyzed 105 patient samples for anti-dsDNA antibodies and results were interpreted as positive or negative according to manufacturer cut-off limits. A multiplex anti-dsDNA immunoassay and an enzyme anti-dsDNA immunoassay assay were investigated as potential alternatives to the Farr-radioisotope immunoassay (RIA).

The BioPlex 2200 multiplex immunoassay (BPx, Bio-Rad Laboratories; Hercules, CA, USA) and the Quanta Lite “Farrzyme” enzyme immunoassay (EIA, INOVA Diagnostics; San Diego, CA, USA) met the stated analytical performance claims, but EIA maintained the widest measurable range. Only 33% SLE patients tested positive on BPx and only 31% with the EIA as compared with the 48% for Farr-RIA. Correlation between Farr-RIA and BPx assay results was poor with 62% positive agreement and 85% negative agreement. There was also poor correlation between the Farr-RIA and EIA with 56% lower positive agreement, but a better negative agreement of 91%.

The mean SLEDAI-2 K scores differed significantly between positive and negative result groups for Farr-RIA and BPx, but not for EIA and the authors suggest suggests it may be appropriate to lower the EIA cut-off point. The authors concluded that the optimal alternative for the Farr-RIA assay remains equivocal. There are ongoing analyses of clinical follow-up and anti-dsDNA measurements, which will aid in determining the most appropriate alternative. The article was published on August 15, 2011, in the journal Clinical Biochemistry.

Related Links:
University Health Network
Bio-Rad Laboratories
INOVA Diagnostics



Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Coagulation Analyzer
CS-2400

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.